Business Wire | Aug 4, 2020 08:00AM EDT

Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Aug. 04, 2020

WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 04, 2020--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals, is scheduled to present on Tuesday, August 11, 2020 at 1:10 p.m. ET.

To access a live webcast and subsequent archived recording of the presentation, please visit the "Investors & Media" section on the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFYTM mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS(r) (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, for which a New Drug Application (NDA) is under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) goal date set for October 30, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005087/en/

CONTACT: Investor Contact: Hannah Deresiewicz hannah.deresiewicz@sternir.com 212-362-1200